# Wei Chen

> Wei Chen is a Series C investor at Oriental Fortune Capital backing Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oriental Fortune Capital](https://shizune.co/investors/profile/oriental-fortune-capital)
- Total investments: 1
- Last investment: Apr 2021
- Lead investor: 0%
- Last updated: Aug 2026

Wei Chen is a Series C investor at Oriental Fortune Capital focused on Biotechnology and Health Diagnostics. Wei Chen is Chairman and Co-Founder of OFC. Prior to founding OFC in 2006, Dr. Chen worked at Shenzhen Capital Group Co., Ltd., the largest venture capital firm in China, serving as President from 2002 to 2006. His investment portfolio companies include Sinovel (SH. 601558), Grandland (SZ. 002047), Sunway (SZ.300136), Wolwo Bio-Pharma (SZ.300357),Prolto Supply (SZ.002769), etc. Over the years, he has won numerous awards, including Forbes China Top Venture Capitalist Zero2IPO Top 10 Venture Capitalist and ChinaVenture Hurun Midas List.Chen holds a Ph.D. in Economics from Xiamen University. He is a distinguished guest professor at Peking University, Tsinghua University, Fudan University, Xiamen University, Xiamen National Accounting Institute, Lanzhou University of Finance and Economics, Cheung Kong Graduate School of Business, China Europe International Business School, and China Capital Market Institute.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 100% |
| Health Diagnostics | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GenomePrecision | Genomeprecision is a molecular diagnostic enterprise integrating R&D, production and sales. It has established “real-time fluorescent quantitative PCR”, “first-generation Sanger sequencing”, “second-generation high-throughput NGS sequencing” and “capillary electrophoresis”. "Fragment Analysis" and "Chemiluminescence CLIA"five molecular diagnostic technology platforms, we will be based on clinical diagnosis and treatment needs to develop molecular diagnostic products based on the above technology platform. | $30.7M | Series C | Apr 19, 2021 |  |

1 of 1 investments shown.

## Co-investors
- [Galaxy Yuanhui Investment](https://shizune.co/investors/profile/galaxy-yuanhui-investment) — VC Fund, 1 deal together
- [Guiyang Venture Capital](https://shizune.co/investors/profile/guiyang-venture-capital) — VC Fund, 1 deal together
- [Juren Capital](https://shizune.co/investors/profile/juren-capital) — VC Fund, 1 deal together
- [Sunland Fund](https://shizune.co/investors/profile/sunland-fund) — VC Fund, 1 deal together
- [Zhongguancun Collaborative Innovation Fund](https://shizune.co/investors/profile/zhongguancun-collaborative-innovation-fund) — VC Fund, 1 deal together

## About Oriental Fortune Capital

VC Fund · Shenzhen, China

Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.

5 contacts available at Oriental Fortune Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Gao Jianguang | Partner | https://shizune.co/investors/profile/gao-jianguang |
| GuoQiang Huang | Deputy General Manager and Partner | https://shizune.co/investors/profile/guoqiang-huang |
| Tang Ruide | Partner | https://shizune.co/investors/profile/tang-ruide |
| Wang Xin | Partner | https://shizune.co/investors/profile/wang-xin-8831 |
| Wei Chen | Founding Partner | https://shizune.co/investors/profile/wei-chen-692a |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Wei Chen invest in?

Wei Chen invests primarily in Biotechnology and Health Diagnostics startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Wei Chen last invest?

The most recent investment recorded for Wei Chen closed in Apr 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co